Assessing Gerotherapeutic Potential of GLP-1 Receptor Agonists
2024
Assessing the Potential of GLP-1 Receptor Agonists in Aging
publication
Author Information
Author(s): Newman John
Primary Institution: Buck Institute for Research on Aging
Hypothesis
Can GLP-1 receptor agonists act as gerotherapeutics to target biological mechanisms of aging?
Conclusion
GLP-1 receptor agonists show promise in reducing age-related diseases, but more research is needed.
Supporting Evidence
- GLP-1 receptor agonists have shown reduced cardiovascular disease and mortality in diabetes patients.
- Current studies are exploring the effects of GLP-1 receptor agonists on Alzheimer's and Parkinson's disease.
Takeaway
Some medicines that help with diabetes might also help people live longer and healthier as they age.
Methodology
The study reviews preclinical and clinical trial data on GLP-1 receptor agonists.
Limitations
Current data on GLP-1 receptor agonists as gerotherapeutics is limited and requires further research.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website